[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide].

Abstract

Different combinations of tuberculostatic drugs containing pyrazinamide were prescribed to 144 patients with pulmonary tuberculosis. In 3 months of treatment, bacterial excretion was observed in 89.7% of newly diagnosed patients and in 59% of cases with chronic forms of pulmonary tuberculosis. Side effects due to pyrazinamide were registered in 16.8% of the patients. In 2-3 months of therapy there were no differences traced in the condition of the liver, lipoid peroxidation or antioxidative activity as well as in a number of immunologic indices both in subjects receiving different combinations of antituberculous drugs, containing pyrazinamide, and in the control group of patients untreated with the drug.

• Authors: M M Savula, M I Smolenko, M D Romaniuk, Iu I Slivka
• Journal: Problemy tuberkuleza (Probl Tuberk) Issue 11 Pg. 25-8 ( 1990) ISSN: 0032-9533 [Print] Russia (Federation)
• Vernacular Title: Klinicheskie i laboratornye issledovaniia u bol'nykh tuberkulezom legkikh, lechennykh pirazinamidom.
• PMID: 2290809 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Antitubercular Agents
• Pyrazinamide

Topics

• Adult
• Aged
• Antitubercular Agents (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Pyrazinamide (administration & dosage)
• Tuberculosis, Pulmonary (drug therapy)